3

R.Minutolo, L.De Nicola, G.Mazzaglia, M.Postorino, C.Cricelli, LG.Mantovani, G.Conte, B.Cianciaruso. Detection and Awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy. Am J Kidn Dis 2008;52(3):444-53.

4

KJ.Jager, PC.van Dijk, C.Zoccali, FW.Dekker. The analysis of survival data: the Kaplan-Meier method. Kidney Int 2008;74(5):560-5.

5

F.Mallamaci. Reflections on 'Survival is not enough-quality of life in CKD'. J Nephrol 2008;21(S13):S163-4.

6

F.Mallamaci, FA.Benedetto, G.Tripepi, S.Cutrupi, P.Pizzini, B.Stancanelli, G.Seminara, G.Bonanno, F.Rapisarda, P.Fatuzzo, LS. Malatino and C.Zoccali. Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. J Hypert 2008,26:1875–1882.

7

F.Perticone, R.Maio, C.Ruberto, S.Cassano, G.Tripepi, M.Perticone, G.Sesti, C.Zoccali.
Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidn Dis 2008;52:74-84.

8

C.Zoccali, D.Abramowicz, JB.Cannata-Andia, P.Cochat, A.Covic, KU.Eckardt, D.Fouque, O.Heimburger et al. European Best Practice Guidelines; European Renal Best Practice. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008;23:2162-6.

9

JB.Cannata-Andia, JL.Fernandez-Martin, C.Zoccali, GM.London, F.Locatelli, M.Ketteler, A.Ferreira, A.Covic et al.  Current Management of Secondary Hyperparathyroidism: a Multicenter Observational Study (COSMOS). J Nephrol 2008;21:290-8.

10

B.Stancanelli, E.Maugeri, A.Nicosia, F.Ferrante, G.Tripepi, C.Zoccali, LS.Malatino. Coronary heart disease extension as a predictor of atherosclerotic renal artery stenosis. J Nephrol 2008;21:421-5.

11

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators with C.Zoccali, FM.Cambareri, G.Parlongo. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46.

12

B.Cianciaruso, P.Ravani, BJ.Barrett, A.Levin; ITA-EPO-7 investigators. Collaborator C.Zoccali. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol 2008;21(6):861-70.

13

JB.Cannata Andia, F.Locatelli, C.Zoccali. The first European Renal Association-European dialysis and transplant association CKD anaemia physician behaviours survey: key findings. J Nephrol 2008;21(2):190-6.

14

C.Zoccali, E.Puntorieri. Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. J Hypertens 2008 Nov;26(11):2096-100.

15

K.Jager, C.Zoccali. What's new at the ERA-EDTA Registry? Port J Nephrol Hypert 2008;22(2):139-141.

16

C.Zoccali, D.Leonardis, F.Mallamaci for Cardio-Sis Study Group. Randomized study of traditional versus aggressive systolic blood pressure control (Cardio-Sis): rationale, design and characteristics of the study population. J Hum Hypertens 2008;22(4):243-51.

17

FA.Benedetto, G.Tripepi, F.Mallamaci, C.Zoccali. Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD. J Am Soc Nephrol 2008;19:757-63.

18

kJ.Jager, C.Zoccali. Quality of care in end-stage renal disease: the importance of comparing 'apples with apples'. Nephrol Dial Transplant 2008;23:1116.

19

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Linear and logistic regression analysis. Kidney Int 2008;73:806-10.

20

C.Zoccali. Cardiovascular risk in patients with chronic kidney disease: not high enough to enter the major league? Curr Hypert Rep 2008;10:1-2.

21

C.Zoccali. Endothelial dysfunction in CKD: a new player in town? Nephrol Dial Transplant 2008;23:783-5.

22

PE.de Jong, M.van der Velde, RT.Gansevoort, C.Zoccali. Screening fo Chronic Kidney Disease: where does Europe go? Clin J Am Soc Nephrol 2008;3:616-23.

23

C.Zoccali, D.Leonardis, G.Enia, M.Postorino, F.Mallamaci on behalf of the MAURO study working group. The MAURO study: Multiple Intervention and Audit in Renal Diseases to Optimize care. J Nephrol 2008;21:20-22.

24

V.Panichi, E.Mantuano, S.Paoletti, S.Santi, G.Manca Rizza, S.Cutrupi, P.Pizzini, B.Spoto, G.Tripepi, C.Zoccali. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008;21:38-44.

25

C.Zoccali, F.Mallamaci, FA.Benedetto, G.Tripepi, P.Pizzini, S.Cutrupi, LS.Malatino. Urotensin II and cardiomyopathy in end-stage renal disease. Hypertension 2008;51:326-33.

26

P.Stella, P.Manunta, F.Mallamaci, M.Melandri, D.Spotti, G.Tripepi, JM.Hamlyn, LS.Malatino, G.Bianchi, C.Zoccali. Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 2008;263:274-80.

27

P.Ravani, G.Tripepi, P.Pecchini, F.Mallamaci, F.Malberti, C.Zoccali. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int 2008;73:95-101.

28

G.Tripepi, KJ.Jager, FW.Dekker, C.Wanner, C.Zoccali. Bias in clinical research. Kidney Int 2008;73:148-53.

29

F.Locatelli, C.Zoccali, SIR SIN Study Investigators. Clinical policies on the Management of Chronic Kidney Disease patients in Italy. Nephrol Dial Transplant 2008;23:621-26.

30

F.Perticone, R.Maio, A.Sciacqua, F.Andreozzi, G.Iemma, M.Perticone, C.Zoccali, G.Sesti. Endothelial Dysfunction and CRP Are Risk Factors for Diabetes in Essential Hypertension. Diabetes 2008;57:167-71.

31

F.Mallamaci. Reflections on ''Survival is not enough-quality of life in CKD''. J Nephrol 2008;21(S13):S163-4.

32

M.Postorino, C.Marino, G.Tripepi, C.Zoccali. Gammaglutamyltransferase in ESRD as a predictor of all-cause and cardiovascular mortality: another facet of oxidative stress burden. Kidney Int 2008;74(S111):S64-S66.

33

KJ.van Stralen, KJ.Jager, C.Zoccali, FW.Dekker. Agreement between methods.
Kidney Int 2008;74(9):1116-20.

34

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Testing for causality and prognosis: etiological and prognostic models. Kidney Int 2008;74(12):1512-5.

35

C.Zoccali, F.Mallamaci. Obesity, diabetes, adiponectin and the kidney: a podocyte affair. Nephrol Dial Transplant 2008;23(12):3767-70.

36

JT.Kielstein, C.Zoccali. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008:17(6):609-615.

37

A.Covic, J.Cannata-Andia, G.Cancarini, R.Coppo, JM,Frazao, D.Goldsmith, P.Ronco, GB.Spasovski, P.Stenvinkel, C.Utas, A.Wiecek, C.Zoccali, G.London. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by ERA-EDTA Council. Nephrol Dial Transplant 2008;23(12):3731-7.

38

F.Mallamaci, D.Leonardis, R.Tripepi, G.Parlongo, C.Catalano, G.Tripepi, V.Castronovo, L.Ferini-Strambi, C.Zoccali. Sleep disordered breathing in renal transplant patients.
Am J Transplant 2009;9:1373-81.

39

G.Quintaliani, G.Cappelli, L.Lodetti, C.Manno, V.Petrucci, C.Spinelli, R.Tarchini, M.Virgilio, M.Faini, S.Alloatti, G.Cancarini, C.Zoccali. Chronic kidney disease certification process manual by the Italian Society of Nephrology (SIN): Part I: clinical care delivery and performance measurements and improvement. J Nephrol 2009;22(4):423-438.

40

C.Zoccali. FGF-23 in dialysis patients: ready for prime time? Nephrol Dial Transplant 2009;24(4):1078-81.

41

B.Stancanelli, LS.Malatino, A.Cataliotti, I.Bellanuova, F.Mallamaci, G.Tripepi, FA.Benedetto, D.Leonardis, P.Fatuzzo, F.Rapisarda, C.Zoccali. Soluble E-Selectin is an inverse and independent predictor of Left Ventricular wall thickness in end-stage renal disease patients. Nephron Clin Pract 2009;114(1):c74-c80.

42

P.Verdecchia, JA.Staessen, F.Angeli et al.; Cardio-Sis Investigators including D.Leonardis. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374(9693):880.

43

M.Postorino, C.Marino, G.Tripepi, C.Zoccali and CREDIT Calabrian Registry of Dialysis and Transplantation Working Group. Abdominal Obesity and all-cause and cardiovascular mortality in end-stage renal diesase. J of Am Coll Cardiol 2009;53:(15):1265-72.

44

BC.Fellstrom, AG.Jardine, RE.Schmieder and AURORA Study Group C.Zoccali, G.Curatola, D.Delfino, G.Caridi, F.Mallamaci, M.Ciccarelli, F.Marino. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360(14):1395-407.

45

C.Zoccali, C.Catalano, S.Rastelli. Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. Nephrol Dial Transplant 2009;24(5):1394-6.

46

AM.Euser, C.Zoccali, KJ.Jager, FW.Dekker. Cohort studies: prospective versus retrospective. Nephron Clin Pract 2009;113(3):c214-c217.

47

R.de Mutsert, KJ.Jager, C.Zoccali, FW.Dekker. The effect of joint exposures: examining the presence of interaction. Kidney Int 2009;75(7):677-81.

48

M.Noordzij, FW.Dekker, C.Zoccali, KJ.Jager. Study designs in clinical research.
Nephron Clin Pract 2009;113(3):c218-c221.

49

DJ.Friedman, M.Afkarian, H.Tamez, I.Bhan, T.Isakova, M.Wolf, E.Ankers, J.Ye, M.Tonelli, C.Zoccali, M.Kuro-O et al.  Klotho variants and chronic hemodialysis mortality. J Bone Miner Res 2009;24(11):1847-55.

50

C.Zoccali. The sweetness of glitazones: randomized trials needed. Nat Rev 2009;5(9):497-8.

51

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Diagnostic methods 2: receiver operating characteristic (ROC) curves. Kidney Int 2009;76(3):252-6.

52

KJ.Jager, C.Zoccali. Comorbidity data collection by renal registries - a remaining challenge. Nephrol Dial Transplant 2009;24(8):2311-3.

53

MI.Yilmaz, A.Sonmez, M.Saglam, M.Gulec, S.Kilic, T.Eyileten, K.Caglar, Y.Oguz, A.Vural, M.Yenicesu, C.Zoccali.  Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney Int 2009;75(12):1316-21.

54

KJ.van Stralen, VS.Stel, JB.Reitsma, FW.Dekker, C.Zoccali, KJ.Jager. Diagnostic methods I: sensitivity, specificity, and other measures of accuracy. Kidney Int 2009;75(12):1257-63.

55

KJ.van Stralen, FW.Dekker, C.Zoccali, KJ.Jager. Case-Control Studies - An efficient observational study design. Nephron Clin Pract 2009;114(1):c1-c4.

56

G.Quintaliani, G.Cappelli, L.Lodetti, C.Manno, V.Petrucci, C.Spinelli, R.Tarchini, M.Virgilio, M.Faini, S.Alloatti, G.Cancarini, C.Zoccali. Chronic kidney disease certification process manual by the Italian Society of Nephrology (SIN): Part II: programme management and  clinical information management. J Nephrol 2009;22(5):565-70.

57

C.Zoccali.  Overweight, obesity and metabolic alterations in chronic kidney disease. Prilozi 2009;30(2):17-31.

58

VS.Stel, C.Zoccali, FW.Dekker, KJ.Jager.  The randomized controlled trial. Nephron Clin Pract 2009;113(4):c337-c342.

59

F.Locatelli, A.Covic, KU.Eckardt, A.Wiecek, R.Vanholder; ERA-EDTA ERBP Advisory Board, collaborator C.Zoccali.  Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24(2):348-54.

60

C.Zoccali, A.Kramer, K.Jager. The databases: renal replacement therapy since 1989 - the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). Clin J Am Soc Nephrol 2009;4(S1):S18-22.

61

C.Zoccali, KDIGO Clinical Practice Guideline for the care of Kidney Transplant Recipients. Kidney Disease: improving global outcomes (KDIGO) Transplant Work Group. Am J Transplant 2009;9(S3):S1-155.

62

P.Ravani, F.Malberti, G.Tripepi, P.Pecchini, S.Cutrupi, P.Pizzini, F.Mallamaci, C.Zoccali. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75(1):88-95.

63

DC.Grootendorst, KJ.Jager, C.Zoccali, FW.Dekker. Observational study are complementary to randomized controlled trials. Nephron Clin Pract 2009;114(2):c173-c177.

64

M.Duranay, M.Kanbay, H.Akay, S.Unverdi, H.Surer, M.Altay, I.Kirbas, A.Covic, C.Zoccali. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot Study. Nephron Clin Pract 2009;114(3):c213-c217.

65

VS.Stel,A.Kramer, C.Zoccali, KJ.Jager. The 2007 ERA-EDTA Registry Annual Report - a précis. NDT Plus 2009;2(6):541-521.

66

F.Aucella, R.Maas, M.Vigliante, G.Tripepi, E.Schwedhelm, M.Margaglione, L.Gesulado, R.Boeger, C.Zoccali.  Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. Atherosclerosis 2009;207(2):541-5.

67

A.Kramer, V.Stel, C.Zoccali, J.Heal, D.Ansell, C.Gronhagen-Riska, T.Leivestad, K.Simpson, R.Palsson, M.Postorino, K.Jager. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 2009;24:3557-3566.

68

F.Mallamaci, C.Zoccali. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease. J Ren Nutr 2009;19(1):25-8.

69

C.Zoccali. The obesity epidemics in ESRD: from wasting to waist? Nephrol Dial Transplant 2009;24(2):376-80.

70

R.Agarwal, AJ.Peixoto, SF.Santos, C.Zoccali.  Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit 2009;14(1):2-11.

71

VS.Stel, A.Kramer, C.Zoccali, KJ.Jager. The 2006 ERA-EDTA Registry annual report: a precis. J Nephrol 2009;22(1):1-12.

72

M.Noordzij, L.Hooft, FW.Dekker, C.Zoccali, KJ.Jager. Systematic reviews and meta-analyses: when they are useful and when to be careful. Kidney Int 2009;76(11):1130.

73

A.Covic, D.Abramowicz, A.Bruchfeld, G.Leroux-Roels, D.Samuel, W.van Biesen, C.Zoccali, F.Zoulim, R.Vanholder; ERA-EDTA ERBP Advisory Board. 

74

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009;24(3):719-27.

75

G.Tripepi, F.Mattace-Raso, F.Mallamaci, FA.Benedetto, J.Witteman, L.Malatino, C.Zoccali. Biomarkers of left atrial volume. A longitudinal study in patients with end stage renal disease. Hypertension 2009;54:818-24.

76

C.Marcantoni, L.Zanoli, S.Rastelli, G.Tripepi, M.Matalone, D.Di Landro, S.Scandura, C.Tamburino, C.Zoccali, P.Castellino. Stenting of Renal Artery Stenosis in Coronary Artery Disease (RAS-CAD) study: a prospective, randomized trial. J Nephrol 2009;22(1):13-6.

77

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Statistical methods for the assessment of prognostic biomarkers (Part I). Discrimination. Nephrol Dial Transplant 2010;25(5):1399-1401.

78

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Statistical methods for the assessment of prognostic biomarkers (part II): calibration and re-classification. Nephrol Dial Transplant 2010;25(5): 1402-05.

79

M.Noordzij, G.Tripepi, FW.Dekker, C.Zoccali, MW.Tanck, KJ.Jager. Sample size calculations: basic principles and common pitfalls. Nephrol Dial Transplant 2010;25(5)-1388-93.

80

A.Testa, F.Mallamaci, FA.Benedetto, A.Pisano, G.Tripepi, L.Malatino, R.Thadhani, C.Zoccali. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010;25(2):131-9.

81

F.Locatelli, P.Altieri, S.Andrulli, P.Bolasco, G.Sau, LA.Pedrini, C.Basile, S.David, M.Feriani, G.Montagna, BR.Di Iorio, B.Memoli, R.Cravero, G.Battaglia, C.Zoccali. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010;21(10):1798-807.

82

M.Verduijn, B.Siegerink, KJ.Jager, C.Zoccali, FW.Dekker. Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrol Dial Transplant 2010;cod1;2010;25(5):1394-98.

83

KJ.van Stralen, FW.Dekker, C.Zoccali, KJ.Jager. Confounding. Nephron Clin Pract 2010;116(2):c143-147.

84

C.Zoccali, A.Kramer, KJ.Jager.  Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010;25(6):1731-3.

85

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Selection bias and information bias in clinical research. Nephron Clin Pract 2010;115(2):c94-c99.

86

P.Ruggenenti, A.Perna, M.Tonelli, G.Loriga, N.Motterlini, N.Rubis, F.Ledda, S.Rota, A.Satta, A.Granata, G.Battaglia, F.Cambareri et al. for ESPLANADE Trial. Effects of Add-on Fluvastatin therapy in patients with chronic proteinuric nephropathy on dual Renin-Angiotensin System blockade: The ESPLANADE Trial. Clin Am Soc Nephrol 2010;5:1928-38.

87

F.Mallamaci, FA.Benedetto, R.Tripepi, S.Rastelli, P.Castellino, G.Tripepi, E.Picano, C.Zoccali. Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC Carrdiovasc Imaging 2010;3(6):586-94.

88

A.Testa, F.Mallamaci, F.Benedetto, A.Pisano, G.Tripepi, L.Malatino, R.Thadhani, C.Zoccali. Vitamin D Receptor (VDR) Gene Polymorphism is associated with Left Ventricular (LV) Mass and predicts LVH progression in end stage renal disease (ESRD) patients. J Bone Miner Res 2010;cod1;2010;25(2):313-19.

89

L.De Nicola, R.Minutolo, P.Chiodini, P.Zamboli, B.Cianciaruso, F.Nappi, S.Signoriello, G.Conte, C.Zoccali. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. Am J Nephrol 2010;32(6):533-40.

90

MI.Yilmaz, A.Sonmez, M.Saglam, H.Yaman, S.Kilic, E.Demirkaya, T.Eyileten, K.Caglar, Y.Oguz, A.Vural, M.Yenicesu, C.Zoccali. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010;78(7):679-685.

91

GP.Rossi, M.Barisa, A.Belfiore, G.Desideri, C.Ferri, C.Letizia, M.Maccario, A.Morganti, G.Palumbo, A.Patalano, E.Roman, TM.Seccia, AC.Pessina, F.Mantero; PAPY Study Investigation F.Mallamaci, G.Caridi, C.Zoccali. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010;cod1;2010;28(9):1892-9.

92

D.Bolignano, C.Zoccali. Vasopressin beyond water: implications for renal diesease. Curr Opin Nephrol Hypertens 2010;19(5):499-504.

93

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Stratification for confounding - Part 2: direct and indirect standardization. Nephron Clin Pract 2010;116(4):c322-c325.

94

C.Zoccali. Left ventricular systolic dysfunction: a sudden killer in end-stage renal disease patients. Hyertension 2010;56(2):187-8.

95

A.Testa, F.Mallamaci, R.Macrì, A.Pisano, B.Spoto, LS.Malatino, B.Stancanelli, G.Tripepi, FA.Benedetto, C.Zoccali. Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. J Hypert 2010;28(8):1745-51.

96

G.Caridi, C.Catalano, G.Enia, C.Zoccali. Noncardiogenic pulmonary edema induced by hydrochlorothiazide. J Nephrol 2010;23(4):483-5.

97

G.Tripepi, KJ.Jager, FW.Dekker, C.Zoccali. Measures of effect in epidemiolocial research. Nephron Clin Pract 2010;115(2):c91-c93.

98

L.De Nicola, R.Minutolo, P.Chiodini, P.Zamboli, B.Cianciaruso, F.Nappi, S.Signoriello, G.Conte, C.Zoccali. Prevalence and Prognosis of Mild Anemia in Non-Dialysis Chronic Kidney Disease: A Prospective Cohort Study in Outpatient Renal Clinics. Am J Nephrol
2010;cod1;2010;32(6):533-40.

99

C.Zoccali, S.Seck. What makes plaques vulnerable in CKD?: a fresh look at metalloproteinases. Kidney Int 2010;78(12):1206-8.

100

MI.Yilmaz, A.Sonmez, M.Karaman, SA.Ay, M.Saglam, H.Yaman, S.Kilic, T.Eyileten, K.Caglar, Y.Oguz, A.Vural, M.Yenicesu, C.Zoccali. Low Triiodothyronine Alters Flow-Mediated Vasodilatation in Advanced Nondiabetic Kidney Disease. Am J Nephrol 2010 Dec 9;33(1):25-32.

101

G.Basta, D.Leonardis, F.Mallamaci, S.Cutrupi, P.Pizzini, L.Gaetano, R.Tripepi, G.Tripepi, R.De Caterina, C.Zoccali. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.
Kidney Int 2010;77(3):225-31.

102

NW.Levin, P.Kotanko, KU.Eckardt, BL.Kasiske, C.Chazot, AK.Cheung, J.Redon, DC.Wheeler, C.Zoccali, GM.London. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: improving global outcomes controversies conference. Kidney Int 2010;77(4):273-84.

103

A.Sonmez, MI.Yilmaz, M.Saglam, S.Kilic, T.Eyileten, G.Uckaya, K.Caglar, Y.Oguz, A.Vural, M.Yenicesu, M.Kutlu, C.Kinalp, C.Zoccali.  The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin J Am Soc Nephrol 2010;5(1):45-50.

104

GP.Rossi, TM.Seccia, G.Palumbo, A.Belfiore, G.Bernini, G.caridi, G.Desideri, B.Fabris, C.Ferri, G.Giacchetti, C.Letizia, M.Maccario, F.Mallamaci, M.Mannelli, A.Patalano, D.Rizzoni, E.Rossi, AC.Pessina, F.Mantero; Primary Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension 2010;55(1):83-9.

105

C.Zoccali, KJ.Jager. Hyperhomocysteinemia: a renal and cardiovascular risk factor? Nat Rev Nephrol 2010;6(12):695-6.

106

KJ.Jager, VS.Stel, C.Zoccali, C.Wanner, FW.Dekker. The issue of studying the effect of interventions in renal replacement therapy -- to what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant 2010;25(12):3836-9.

107

DJ.Goldsmith, A.Covic, D.Fouque, F.Locatelli, K.Olgaard, M.Rodriguez, G.Spasovski, P.Urena, C.Zoccali, GM.London, R.Vanholder. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010;25(12):3823-31.

108

M.Noordzij, FW.Dekker, C.Zoccali, KJ.Jager. Measures of diseases frequency: prevalence and incidence. Nephron Clin Pract 2010;115(1):c17-c20.

109

G.Tripepi, F.Mattace-Raso, F.Rapisarda, B.Stancanelli, L.Malatino, J.Witteman, C.Zoccali, F.Mallamaci. Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. J Hypert 2010;28:2468-74.

110

D.Leonardis, G.Basta, F.Mallamaci, S.Cutrupi, P.Pizzini, R.Tripepi, G.Tripepi, R.De Caterina, C.Zoccali. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2011 Apr 4. [Epub ahead of print]

111

C.Zoccali. Left ventricular mass index as an outcome measure in clinical trials in dialysis patients: a word of caution. Am J Nephrol 2011;33(4):370-372.

112

F.Mallamaci, G.Tripepi. Comment accompanying obstructive sleep apnoea: a stand-alone risk factor for chronic kidney disease. Nephrol Dial Transplant 2011;26:2072-2074.

113

C.Marcantoni, S.Castellino, T.Cicchetti, F.Mallamaci, S.Rastelli. Women and the sciences. J Nephrol 2011;24(3):386-389.

114

MC.Postorino, M.Bellantoni, C.Catalano, G.Caridi, M.De Rosa, S.Seck, G.Enia. Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case. J Nephrol 2011;24(4):530-534.

115

C.Zoccali, G.Serravalle, G.Grassi. Sympathoinhibitory effects of statins in chronic kidney disease: are they clinically relevant? J Hypertens 2011;29(11):2064-7.

116

M.Noordzij, C.Zoccali, FW.Dekker, KJ.Jager. Adding up the evidence: systematic reviews and meta-analyses. Nephron Clin Pract  2011;119(4):c310-6.

117

G.Grassi, G.Seravalle, L.Ghiadoni, G.Tripepi, RM.Bruno, G.Mancia, C.Zoccali. Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. Clin J Am Soc Nephrol 2011;6(11):2620-7.

118

G.Tripepi, F.Mattace-Raso, E.Sijbrands, J.Witteman, F.Rapisarda, L.Malatino, F.Mallamaci, C.Zoccali. Aging and Left Ventricular Mass and Function in People with End-Stage Renal Disease. J Am Geriatr Soc 2011;59(9):1636-41.

119

DJ.de Jager, R.de Mutsert, KJ.Jager, C.Zoccali, FW.Dekker. Reporting of interaction. Nephron Clin Pract. 2011;119(2):c158-61.

120

R.de Mutsert, DJ.de Jager, KJ.Jager, C.Zoccali, FW.Dekker. Interaction on an additive scale. Nephron Clin Pract. 2011;119(2):c154-7.

121

C.Zoccali, P.Ruggenenti, A.Perna, D.Leonardis, R.Tripepi, G.Tripepi, F.Mallamaci, G.Remuzzi; for the REIN Study Group. Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. J Am Soc Nephrol. 2011 Oct;22(10):1923-1930.

122

VS.Stel, FW.Dekker, G.Tripepi, C.Zoccali, KJ.Jager. Survival Analysis II: Cox Regression. Nephron Clin Pract. 2011 Sep 14;119(3):c255-c260.

123

M.Verduijn, KJ.Jager, C.Zoccali, FW.Dekker. Genetic Association Studies: Discovery of the Genetic Basis of Renal Disease. Nephron Clin Pract. 2011 Aug 18;119(3):c236-c239.

124

L.De Nicola, P.Chiodini, C.Zoccali, S.Borrelli, B.Cianciaruso, B.Di Iorio, D.Santoro, V.Giancaspro, C.Abaterusso, C.Gallo, G.Conte, R.Minutolo; for the SIN-TABLE CKD Study Group. Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. Clin J Am Soc Nephrol. 2011 Oct;6(10):2421-2428.

125

C.Zoccali, SM.Seck, F.Mallamaci. Obesity and the epidemiology and prevention of kidney disease: waist circumference versus body mass index. Am J Kidney Dis. 2011 Aug;58(2):157-9.

126

VS.Stel, FW.Dekker, G.Tripepi, C.Zoccali, KJ.Jager. Survival analysis I: the Kaplan-Meier method. Nephron Clin Pract. 2011;119(1):c83-8.

127

G.Tripepi, F.Mattace Raso, E.Sijbrands, MS.Seck, R.Maas, R.Boger, J.Witteman, F.Rapisarda, L.Malatino, F.Mallamaci, C.Zoccali. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol. 2011 Jul;6(7):1714-21.

128

M.Postorino, C.Marino, G.Tripepi, C.Zoccali on behalf of CREDIT Working Group
Abdominal obesity modifies the risk of hypertriglyceridemia for a all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int  2011:79(7):765-72.

129

M.Noordzij, FW.Dekker, C.Zoccali, KJ.Jager. Sample size calculations. Nephron Clin Pract 2011:118(4):c319-c323.

130

MA.de Graaf, KJ.Jager, C.Zoccali, FW.Dekker. Matching, an appealing method to avoid confounding? Nephron Clin Pract 2011:118(4):c315-c318.

131

G.Tripepi, KJ.Jager, V.Steel, FW.Dekker, C.Zoccali. How to deal with continuous and dichotomic outcomes in epidemiological research: linear and logistic regression analyses. Nephron Clin Pract 2011:118(4):c399-c406.

132

C.Zoccali, S.Seck. The dilemma of making recommendations based on weak evidence. Semin Dial 2011:24(1):27-9.

133

C.Zoccali, F.Mallamaci. Does adipose tissue have a key role in inflammation in CKD? J Intern Med 2011:269(4):407-9.

134

R.Thadhani, E.Appelbaum, Y.Chang, Y.Pritchett, I.Bhan, R.Agarwal, C.Zoccali, C.Wanner, D.Lloyd-Jones, J.Cannata, T.Thompson et al.  Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol
2011:33(2):139-49.

135

F.Mallamaci, P.Ruggenenti, A.Perna, D.Leonardis, R.Tripepi, G.Tripepi, G.Remuzzi, C.Zoccali; for the REIN Study Group. ACE inhibition is renoprotective among obese patients with proteinuria. J AM Soc Nephrol 2011;22(6):1122-1128.

136

Y.Pritchett, Y.Jemiai, Y.Chang, I.Bhan, R.Agarwal, C.Zoccali, C.Wanner, D.Lloyd-Jones, JB.Cannata-Andía, T.Thompson, E.Appelbaum, P.Audhya, D.Andress, W.Zhang, S.Solomon, WJ.Manning, R.Thadhani. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials 2011;8(2):165-74.

137

S.Bacci, S.Rizza, S.Prudente, B.Spoto, C.Powers, A.Facciorusso, A.Pacilli, D.Lauro, A.Testa, YY.Zhang, G.Di Stolfo, F.Mallamac, G.Tripepi, R.Xu, D.Mangiacotti, F.Aucella, R.Lauro, EV.Gervino, TH.Hauser, M.Copetti, S.De Cosmo, F.Pellegrini, C.Zoccali, M.Federici, A.Doria, V.Trischitta. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes 2011;60(3):1000-7.

138

VS.Stel, FW.Dekker, G.Tripepi, C.Zoccali, KJ.Jager. Survival Analysis I: The Kaplan-Meier Method. Nephron Clin Pract 2011;119(1):c83-c88.

139

G.Tripepi, FR.Mattace, E.Sijbrands, MS.Seck, R.Maas, R.Boger, J.Witteman, F.Rapisarda, L.Malatino, F.Mallamaci, C.Zoccali.  Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011;6(7):1714-21.

140

J.Tattersall, f.Dekker, O.Heimbürger, KJ.Jager, N.Lameire, E.Lindley, W.Van Biesen, R.Vanholder, C.Zoccali on behalf of the ERBP Advisory board.  When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant 2011;26(7):2082-2086.

141

G.Curatola, D.Bolignano, S.Rastelli, G.Caridi, R.Tripepi, G.Tripepi, R.Politi, F.Catalano, D.Delfino, M.Ciccarelli, F.Mallamaci, C.Zoccali. Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. J Nephrol 2011;24(4):465-73.

142

C.Zoccali, F.Mallamaci. Adiponectin and Leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 2011:21(1):87-91.

143

C.Zoccali, M.Postorino, C.Marino, P.Pizzini, S.Cutrupi, G.Tripepi: on behalf of the CREDIT Working Group. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 2011:269(2):172-181.

144

C.Zoccali.  Left ventricular mass index as an outcome measure in clinical trials in dialysis patients: a word of caution. Am J Nephrol 2011;33(4):370-372.